Switch theme
Sign up to access all valuation multiples
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
2013
61
LTM Revenue $8.8M
LTM EBITDA -$185M
$153M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abivax has a last 12-month revenue of $8.8M and a last 12-month EBITDA of -$185M.
In the most recent fiscal year, Abivax achieved revenue of n/a and an EBITDA of -$145M.
Abivax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abivax valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $9.2M | XXX | XXX | XXX |
| Gross Profit | -$49.7M | -$55.4M | XXX | XXX | XXX |
| Gross Margin | -Infinity% | -601% | XXX | XXX | XXX |
| EBITDA | -$145M | -$182M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -1969% | XXX | XXX | XXX |
| Net Profit | -$45.2M | -$76.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -827% | XXX | XXX | XXX |
| Net Debt | n/a | $20.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Abivax's stock price is EUR 5 (or $6).
Abivax has current market cap of EUR 346M (or $378M), and EV of EUR 141M (or $153M).
See Abivax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $378M | XXX | XXX | XXX | XXX | $-2.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Abivax has market cap of $378M and EV of $153M.
Abivax's trades at 17.5x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.
Analysts estimate Abivax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Abivax and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $153M | XXX | XXX | XXX |
| EV/Revenue | 16.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | XXX | XXX |
| P/E | -2.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAbivax's NTM/LTM revenue growth is -22%
Abivax's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.3M for the same period.
Over next 12 months, Abivax's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Abivax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Abivax and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1969% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1991% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abivax acquired XXX companies to date.
Last acquisition by Abivax was XXXXXXXX, XXXXX XXXXX XXXXXX . Abivax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Abivax founded? | Abivax was founded in 2013. |
| Where is Abivax headquartered? | Abivax is headquartered in France. |
| How many employees does Abivax have? | As of today, Abivax has 61 employees. |
| Who is the CEO of Abivax? | Abivax's CEO is Mr. Marc de Garidel. |
| Is Abivax publicy listed? | Yes, Abivax is a public company listed on PAR. |
| What is the stock symbol of Abivax? | Abivax trades under ABVX ticker. |
| When did Abivax go public? | Abivax went public in 2015. |
| Who are competitors of Abivax? | Similar companies to Abivax include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Abivax? | Abivax's current market cap is $378M |
| What is the current revenue of Abivax? | Abivax's last 12-month revenue is $8.8M. |
| What is the current EBITDA of Abivax? | Abivax's last 12-month EBITDA is -$185M. |
| What is the current EV/Revenue multiple of Abivax? | Current revenue multiple of Abivax is 17.5x. |
| What is the current EV/EBITDA multiple of Abivax? | Current EBITDA multiple of Abivax is -0.8x. |
| Is Abivax profitable? | Yes, Abivax is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
